AVCT Avacta Group Plc

TIDMAVCT

RNS Number : 6126Y

Avacta Group PLC

10 September 2015

 
 10 September 2015 
 

Avacta Group plc

("Avacta", the "Company" or the "Group")

Total Voting Rights

The Company would like to confirm that Avacta's issued share capital consists of 6,740,649,550 Ordinary Shares of 0.1p each with voting rights, and not 6,740,149,550 as was incorrectly stated in the Company's announcement on 3 September 2015.

The above figure of 6,740,649,550 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules. The Company does not hold any shares in Treasury.

- Ends -

For further information:

 
 Avacta Group plc                                  Tel: +44 (0) 844 414 
  Tim Sykes, Chief Financial Officer                0452 
                                                    www.avacta.com 
 
   Numis Securities Limited                          Tel: +44 (0) 207 260 
   Michael Meade / Freddie Barnfield - Nominated     1000 
   Adviser                                           www.numiscorp.com 
   James Black - Corporate Broking 
 
   Media Enquiries                                   Tel: +44 (0) 20 3727 
   FTI Consulting                                    1000 
   Simon Conway/Natalie Garland-Collins              avacta@fticonsulting.com 
 

About Avacta Group plc - www.avacta.com

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through two divisions:

 
 Avacta Animal Health          Veterinary diagnostics reference laboratory 
  www.avactaanimalhealth.com    and diagnostic kit provider. 
 Avacta Life Sciences          Novel non-antibody affinity reagents 
  www.avactalifesciences.com    called Affimers, with a wide range of 
                                Life Science applications in diagnostics, 
                                drug and biomarker discover and biotech 
                                research and development. 
                              -------------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRLKLLBEKFLBBV

(END) Dow Jones Newswires

September 10, 2015 02:01 ET (06:01 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024